AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:ABBV
- CUSIP: 00287Y10
- Web: www.abbvie.com
Capitalization:- Market Cap: $114.38 billion
- Outstanding Shares: 1,594,094,000
Average Prices:- 50 Day Moving Avg: $71.67
- 200 Day Moving Avg: $67.26
- 52 Week Range: $55.06 - $75.04
P/E:- Trailing P/E Ratio: 17.65
- Foreward P/E Ratio: 11.07
- P/E Growth: 0.92
Sales & Book Value:- Annual Revenue: $26.71 billion
- Price / Sales: 4.28
- Book Value: $3.77 per share
- Price / Book: 19.03
Dividend:- Annual Dividend: $2.56
- Dividend Yield: 3.7%
Profitability:- EBIDTA: $11.57 billion
- Net Margins: 24.77%
- Return on Equity: 150.27%
- Return on Assets: 12.52%
Debt:- Debt-to-Equity Ratio: 5.63%
- Current Ratio: 1.38%
- Quick Ratio: 1.25%
Misc:- Average Volume: 5.17 million shs.
- Beta: 1.5
- Short Ratio: 5.37
Frequently Asked Questions for AbbVie (NYSE:ABBV)
What is AbbVie's stock symbol?
AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?
AbbVie announced a quarterly dividend on Friday, June 23rd. Stockholders of record on Friday, July 14th will be given a dividend of $0.64 per share on Tuesday, August 15th. This represents a $2.56 annualized dividend and a dividend yield of 3.57%. The ex-dividend date of this dividend is Wednesday, July 12th. View AbbVie's Dividend History.
How will AbbVie's stock buyback program work?
AbbVie announced that its board has initiated a stock repurchase program on Sunday, April 9th 2017, which authorizes the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 5% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's board believes its shares are undervalued.
How were AbbVie's earnings last quarter?
AbbVie Inc. (NYSE:ABBV) announced its quarterly earnings results on Friday, July, 28th. The company reported $1.42 EPS for the quarter, beating analysts' consensus estimates of $1.40 by $0.02. The firm earned $6.94 billion during the quarter, compared to analyst estimates of $6.93 billion. AbbVie had a net margin of 24.77% and a return on equity of 150.27%. The firm's revenue was up 7.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.26 EPS. View AbbVie's Earnings History.
When will AbbVie make its next earnings announcement?
What guidance has AbbVie issued on next quarter's earnings?
AbbVie updated its FY17 earnings guidance on Friday, July, 28th. The company provided earnings per share guidance of $5.44-5.54 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.53.
Where is AbbVie's stock going? Where will AbbVie's stock price be in 2017?
14 equities research analysts have issued 1-year target prices for AbbVie's shares. Their predictions range from $60.00 to $95.00. On average, they expect AbbVie's stock price to reach $76.31 in the next twelve months. View Analyst Ratings for AbbVie.
What are analysts saying about AbbVie stock?
Here are some recent quotes from research analysts about AbbVie stock:
- 1. According to Zacks Investment Research, "AbbVie’s key drug Humira is performing well and should continue to be driven by growing awareness, favorable clinical data, new indications and expansion into new markets. Moreover, Imbruvica has multi-billion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Investor focus will be on the stock with several late-stage data-readouts are expected in 2017. AbbVie’s shares outperformed the large-cap pharma industry so far this year. However, Viekira faces intense pricing and competitive pressure in the HCV market. Though Humira is doing well, the company is concerned about the product’s long-term prospects owing to the potential biosimilar competition. Estimates remained stable ahead of the company’s Q2 earnings release. AbbVie has had a mixed record of earnings surprises in the recent quarters. " (7/13/2017)
- 2. Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)
Are investors shorting AbbVie?
AbbVie saw a decrease in short interest in July. As of July 14th, there was short interest totalling 20,721,827 shares, a decrease of 15.1% from the June 30th total of 24,405,917 shares. Based on an average daily trading volume, of 4,123,053 shares, the short-interest ratio is currently 5.0 days. Currently, 1.3% of the shares of the stock are sold short.
Who are some of AbbVie's key competitors?
Some companies that are related to AbbVie include ConvaTec Group PLC (CTEC), Mallinckrodt PLC (MNK), Indivior PLC (INDV), Supernus Pharmaceuticals (SUPN), Advanced Accelerator Applications S.A. (AAAP), Repligen Corporation (RGEN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Aimmune Therapeutics (AIMT), Eagle Pharmaceuticals (EGRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), Novan (NOVN), Check-Cap (CHEK), CorMedix (CRMD), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).
Who are AbbVie's key executives?
AbbVie's management team includes the folowing people:
- Richard A. Gonzalez, Chairman of the Board, Chief Executive Officer
- William J. Chase, Executive Vice President, Chief Financial Officer
- Michael Severino M.D., Executive Vice President - Research & Development, Chief Scientific Officer
- Laura J. Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary
- Carlos Alban, Executive Vice President - Commercial Operations
- Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer
- Timothy J. Richmond, Senior Vice President - Human Resources
- Azita Saleki-Gerhardt Ph.D., Senior Vice President - Operations
- Robert A. Michael, Vice President, Controller
- Robert J. Alpern M.D., Independent Director
Who owns AbbVie stock?
AbbVie's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (11.18%), Vanguard Group Inc. (7.28%), BlackRock Inc. (5.91%), State Street Corp (4.48%), Northern Trust Corp (1.33%) and Bank of New York Mellon Corp (1.07%). Company insiders that own AbbVie stock include Carlos Alban, Edward J Rapp, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.
Who sold AbbVie stock? Who is selling AbbVie stock?
AbbVie's stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Glenview Capital Management LLC, Bank of New York Mellon Corp, Canada Pension Plan Investment Board, AXA, APG Asset Management N.V., Prudential PLC and Strs Ohio. Company insiders that have sold AbbVie stock in the last year include Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.
Who bought AbbVie stock? Who is buying AbbVie stock?
AbbVie's stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Janus Henderson Group PLC, Orbis Allan Gray Ltd, Capital Research Global Investors, BlackRock Inc., Prudential Financial Inc., Balyasny Asset Management LLC and Renaissance Technologies LLC. View Insider Buying and Selling for AbbVie.
How do I buy AbbVie stock?
Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AbbVie's stock price today?
One share of AbbVie stock can currently be purchased for approximately $71.75.
MarketBeat Community Rating for AbbVie (NYSE ABBV)MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for AbbVie (NYSE:ABBV) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 7 Hold Ratings, 6 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 2.57) |
| Consensus Price Target: | $76.31 (6.35% upside) |
Analysts' Ratings History for AbbVie (NYSE:ABBV)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/16/2017 | Evercore ISI | Initiated Coverage | Outperform -> Outperform | $95.00 | Medium |  |
| 8/3/2017 | Piper Jaffray Companies | Reiterated Rating | Buy | $85.00 | Low | |
| 7/30/2017 | Cowen and Company | Set Price Target | Hold | $70.00 | Low | |
| 7/20/2017 | Credit Suisse Group | Reiterated Rating | Neutral | $65.00 -> $74.00 | Medium | |
| 7/17/2017 | Deutsche Bank AG | Reiterated Rating | Hold | $65.00 -> $66.00 | Low | |
| 7/17/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $92.00 -> $94.00 | Low | |
| 6/22/2017 | Leerink Swann | Reiterated Rating | Market Perform | | Low | |
| 6/22/2017 | Societe Generale | Upgrade | Hold -> Buy | | Low | |
| 5/17/2017 | BMO Capital Markets | Reiterated Rating | Market Perform | $66.00 | Low | |
| 3/11/2017 | Goldman Sachs Group, Inc. (The) | Upgrade | Buy -> Conviction-Buy | $74.00 -> $80.00 | N/A | |
| 12/8/2016 | William Blair | Reiterated Rating | Outperform | $76.00 | N/A | |
| 11/28/2016 | Citigroup Inc. | Downgrade | Buy -> Neutral | $60.00 | N/A | |
| 9/8/2016 | J P Morgan Chase & Co | Downgrade | Overweight -> Neutral | $75.00 -> $73.00 | N/A | |
| 9/1/2016 | Raymond James Financial, Inc. | Initiated Coverage | Outperform | $82.00 | N/A | |
| 8/8/2016 | Argus | Reiterated Rating | Buy | $85.00 | N/A | |
| 8/2/2016 | Barclays PLC | Reiterated Rating | Equal Weight | $68.00 | N/A | |
| 6/8/2016 | Morgan Stanley | Downgrade | Overweight -> Equal Weight | $73.00 -> $65.00 | N/A | |
| 12/18/2015 | Atlantic Securities | Initiated Coverage | Neutral | $59.00 | N/A | |
(Data available from 8/23/2015 forward)
Earnings History for AbbVie (NYSE:ABBV)Earnings History by Quarter for AbbVie (NYSE ABBV)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/26/2017 | | $1.38 | | | | | N/A | |
| 7/28/2017 | Q2 2017 | $1.40 | $1.42 | $6.93 billion | $6.94 billion | View | N/A | |
| 4/27/2017 | Q1 2017 | $1.26 | $1.28 | $6.49 billion | $6.54 billion | View | N/A | |
| 1/27/2017 | Q416 | $1.20 | $1.20 | $6.92 billion | $6.78 billion | View | Listen | |
| 10/28/2016 | Q316 | $1.21 | $1.21 | $6.55 billion | $6.43 billion | View | Listen | |
| 7/29/2016 | Q216 | $1.20 | $1.26 | $6.20 billion | $6.43 billion | View | Listen | |
| 4/28/2016 | Q116 | $1.14 | $1.15 | $6.03 billion | $5.96 billion | View | Listen | |
| 1/29/2016 | Q415 | $1.12 | $1.13 | $6.41 billion | $6.36 billion | View | Listen | |
| 10/30/2015 | Q315 | $1.08 | $1.13 | $5.90 billion | $4.94 billion | View | Listen | |
| 7/24/2015 | Q215 | $1.06 | $1.08 | $5.60 billion | $5.48 billion | View | Listen | |
| 4/23/2015 | Q115 | $0.85 | $0.94 | $718.50 million | $5.04 billion | View | Listen | |
| 1/30/2015 | Q414 | $0.86 | $0.89 | $5.34 billion | $5.45 billion | View | Listen | |
| 10/31/2014 | Q3 | $0.77 | $0.89 | $4.82 million | $5.02 million | View | Listen | |
| 7/25/2014 | Q214 | $0.76 | $0.82 | $4.70 billion | $4.93 billion | View | Listen | |
| 4/25/2014 | Q114 | $0.68 | $0.71 | $4.33 billion | $4.56 billion | View | Listen | |
| 1/31/2014 | Q413 | $0.82 | $0.82 | $5.10 billion | $5.11 billion | View | Listen | |
| 10/25/2013 | Q313 | $0.78 | $0.82 | $4.52 billion | $4.66 billion | View | Listen | |
| 7/26/2013 | Q2 2013 | $0.79 | $0.92 | $4.54 billion | $4.69 billion | View | Listen | |
| 4/26/2013 | Q1 2013 | $0.67 | $0.68 | $4.17 billion | $4.33 billion | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for AbbVie (NYSE:ABBV)Current Year EPS Consensus Estimate: $5.52 EPS
Next Year EPS Consensus Estimate: $6.48 EPS
Current Dividend Information for AbbVie (NYSE:ABBV)| Most Recent Dividend: | 8/15/2017 |
| Annual Dividend: | $2.56 |
| Dividend Yield: | 3.57% |
| Dividend Growth: | 12.50% (3 Year Average) |
| Payout Ratio: | 62.90% (Trailing 12 Months of Earnings)
46.38% (Based on This Year's Estimates)
39.51% (Based on Next Year's Estimates)
|
| Track Record: | 44 Years of Consecutive Dividend Growth |
Dividend History by Quarter for AbbVie (NYSE ABBV)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 6/23/2017 | quarterly | $0.64 | 3.52% | 7/12/2017 | 7/14/2017 | 8/15/2017 |
| 2/17/2017 | quarterly | $0.64 | 4.14% | 4/11/2017 | 4/13/2017 | 5/15/2017 |
| 10/28/2016 | quarterly | $0.64 | 4.44% | 1/11/2017 | 1/13/2017 | 2/15/2017 |
| 9/12/2016 | quarterly | $0.57 | 3.56% | 10/12/2016 | 10/14/2016 | 11/15/2016 |
| 6/17/2016 | quarterly | $0.57 | 3.8% | 7/13/2016 | 7/15/2016 | 8/15/2016 |
| 2/19/2016 | quarterly | $0.57 | 4.2% | 4/13/2016 | 4/15/2016 | 5/16/2016 |
| 11/2/2015 | quarterly | $0.57 | 3.6% | 1/13/2016 | 1/15/2016 | 2/16/2016 |
| 9/14/2015 | quarterly | $0.51 | 3.46% | 10/13/2015 | 10/15/2015 | 11/14/2015 |
| 6/19/2015 | quarterly | $0.51 | 2.94% | 7/13/2015 | 7/15/2015 | 8/14/2015 |
| 2/20/2015 | quarterly | $0.51 | 3.33% | 4/13/2015 | 4/15/2015 | 5/15/2015 |
| 10/20/2014 | quarterly | $0.49 | 3.48% | 1/13/2015 | 1/15/2015 | 2/13/2015 |
| 9/19/2014 | quarterly | $0.42 | 2.86% | 10/10/2014 | 10/15/2014 | 11/17/2014 |
| 6/19/2014 | quarterly | $0.42 | 3.15% | 7/11/2014 | 7/15/2014 | 8/15/2014 |
| 2/20/2014 | quarterly | $0.42 | 3.29% | 4/11/2014 | 4/15/2014 | 5/15/2014 |
| 12/12/2013 | quarterly | $0.40 | 3.06% | 1/13/2014 | 1/15/2014 | 2/14/2014 |
| 9/19/2013 | quarterly | $0.40 | 3.34% | 10/10/2013 | 10/15/2013 | 11/15/2013 |
| 6/20/2013 | quarterly | $0.40 | 3.75% | 7/11/2013 | 7/15/2013 | 8/15/2013 |
| 2/15/2013 | quarterly | $0.40 | 4.19% | 4/11/2013 | 4/15/2013 | 5/15/2013 |
| 1/7/2013 | special | $0.40 | | 1/11/2013 | 1/15/2013 | 2/15/2013 |
| 1/4/2013 | quarterly | $0.40 | | | 1/15/2013 | 2/15/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for AbbVie (NYSE:ABBV)Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 67.69%
Insider Trades by Quarter for AbbVie (NYSE:ABBV)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/7/2017 | Richard A Gonzalez | Chairman | Sell | 193,131 | $71.00 | $13,712,301.00 | |
| 8/4/2017 | Richard A Gonzalez | Chairman | Sell | 87,899 | $71.02 | $6,242,586.98 | |
| 8/3/2017 | Richard A Gonzalez | CEO | Sell | 65,861 | $71.00 | $4,676,131.00 | |
| 7/31/2017 | Edward J Rapp | Director | Buy | 4,000 | $70.45 | $281,800.00 | |
| 7/31/2017 | Henry O Gosebruch | Insider | Sell | 18,000 | $70.09 | $1,261,620.00 | |
| 6/14/2017 | Carlos Alban | EVP | Sell | 45,800 | $70.00 | $3,206,000.00 | |
| 6/14/2017 | Laura J Schumacher | Insider | Sell | 79,800 | $70.00 | $5,586,000.00 | |
| 5/19/2017 | Richard A Gonzalez | Chairman | Sell | 71,235 | $65.49 | $4,665,180.15 | |
| 5/18/2017 | William J Chase | CFO | Sell | 38,300 | $65.35 | $2,502,905.00 | |
| 5/4/2017 | Carlos Alban | EVP | Sell | 43,000 | $67.00 | $2,881,000.00 | |
| 3/10/2017 | Laura J Schumacher | Insider | Sell | 40,000 | $65.26 | $2,610,400.00 | |
| 3/10/2017 | Robert A Michael | VP | Sell | 5,132 | $65.29 | $335,068.28 | |
| 3/10/2017 | Timothy J Richmond | SVP | Sell | 22,451 | $65.29 | $1,465,825.79 | |
| 3/8/2017 | Richard A Gonzalez | Chairman | Sell | 72,016 | $64.25 | $4,627,028.00 | |
| 12/2/2016 | William J Chase | CFO | Sell | 6,600 | $59.19 | $390,654.00 | |
| 9/7/2016 | Laura J Schumacher | Insider | Sell | 50,000 | $65.00 | $3,250,000.00 | |
| 6/24/2016 | Laura J Schumacher | EVP | Sell | 186,106 | $60.03 | $11,171,943.18 | |
| 6/2/2016 | Richard A Gonzalez | CEO | Sell | 285,953 | $63.82 | $18,249,520.46 | |
| 5/11/2016 | Richard A Gonzalez | CEO | Sell | 39,000 | $63.80 | $2,488,200.00 | |
| 5/10/2016 | Carlos Alban | EVP | Sell | 47,438 | $63.52 | $3,013,261.76 | |
| 5/10/2016 | Thomas A Hurwich | VP | Sell | 6,000 | $63.59 | $381,540.00 | |
| 5/10/2016 | Timothy J Richmond | SVP | Sell | 21,583 | $63.52 | $1,370,952.16 | |
| 3/8/2016 | Laura J Schumacher | EVP | Sell | 25,000 | $56.09 | $1,402,250.00 | |
| 3/1/2016 | Timothy J Richmond | SVP | Sell | 12,866 | $55.05 | $708,273.30 | |
| 4/28/2015 | Richard A Gonzalez | CEO | Sell | 102,964 | $64.67 | $6,658,681.88 | |
| 3/2/2015 | Laura J Schumacher | EVP | Sell | 25,000 | $60.30 | $1,507,500.00 | |
| 3/2/2015 | Timothy J Richmond | SVP | Sell | 14,388 | $60.33 | $868,028.04 | |
| 12/22/2014 | William J Chase | CFO | Sell | 8,495 | $68.00 | $577,660.00 | |
| 3/4/2014 | Richard Gonzalez | CEO | Sell | 4,799 | $51.20 | $245,708.80 | |
| 3/3/2014 | Azita Saleki-Gerhardt | SVP | Sell | 2,443 | $50.25 | $122,760.75 | |
| 3/3/2014 | Carlos Alban | EVP | Sell | 2,882 | $50.09 | $144,359.38 | |
| 3/3/2014 | William Chase | CFO | Sell | 3,948 | $50.22 | $198,268.56 | |
| 9/17/2013 | Azita Saleki-Gerhardt | SVP | Sell | 10,473 | $45.84 | $480,082.32 | |
| 8/19/2013 | Azita Saleki-Gerhardt | SVP | Sell | 1,270 | $43.01 | $54,622.70 | |
| 8/12/2013 | Azita Saleki-Gerhardt | SVP | Sell | 8,851 | $44.91 | $397,498.41 | |
| 3/11/2013 | Edward J Rapp | Director | Buy | 2,500 | $37.67 | $94,175.00 | |
| 2/4/2013 | Frederick H Waddell | Director | Buy | 2,000 | $37.05 | $74,100.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for AbbVie (NYSE:ABBV)
Latest Headlines for AbbVie (NYSE:ABBV)
| Source: |
|
| Date | Headline |
|---|
 | AbbVie May Become The New Teva - Seeking Alpha
seekingalpha.com - August 22 at 8:28 PM |
 | 5 of the Most Popular Stocks in Hedge Fund Portfolios, Revealed
finance.yahoo.com - August 22 at 3:25 PM |
 | Eagle Pharmaceuticals (EGRX) vs. AbbVie (ABBV) Head to Head Analysis
www.americanbankingnews.com - August 22 at 4:08 AM |
| Analysts Anticipate AbbVie Inc. (ABBV) Will Announce Earnings of $1.38 Per Share
www.americanbankingnews.com - August 22 at 4:04 AM |
| AbbVie Inc: Ain't Broke, Don't Fix - Seeking Alpha
seekingalpha.com - August 21 at 3:23 PM |
| Gilead: Where's the Urgency?
finance.yahoo.com - August 21 at 3:23 PM |
 | Better Buy: AbbVie Inc. vs. Pfizer Inc.
www.fool.com - August 21 at 8:26 AM |
 | AbbVie's HCV Combo Drug Mavyret Clinches Approval in Canada
www.zacks.com - August 18 at 8:22 PM |
 | AbbVie's HCV Combo Drug Mavyret Clinches Approval in Canada - Nasdaq
www.nasdaq.com - August 18 at 3:19 PM |
| Alyeska Investment Group, LP Buys Delta Air Lines Inc, AbbVie Inc, Reynolds American Inc, ... - Nasdaq
www.nasdaq.com - August 18 at 3:19 PM |
| AbbVie's HCV Combo Drug Mavyret Clinches Approval in Canada
finance.yahoo.com - August 18 at 3:19 PM |
 | Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst - TheStreet.com
www.thestreet.com - August 17 at 3:32 PM |
| AbbVie's MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes
finance.yahoo.com - August 17 at 3:32 PM |
| Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst
finance.yahoo.com - August 17 at 3:32 PM |
| AbbVie's HCV med Maviret OK'd in Canada
seekingalpha.com - August 17 at 10:23 AM |
| Very Cautious On AbbVie's Fundamentals - Seeking Alpha
seekingalpha.com - August 17 at 1:21 AM |
| AbbVie Inc. (ABBV) Receives New Coverage from Analysts at Evercore ISI
www.americanbankingnews.com - August 16 at 6:26 PM |
| Kitzinger Lautmann Capital Management Inc Buys Abbott Laboratories, AbbVie Inc, Philip Morris ...
www.nasdaq.com - August 16 at 3:20 PM |
| What Does AbbVie’s Dividend Curve Look Like?
finance.yahoo.com - August 16 at 3:19 PM |
| AbbVie Inc. (ABBV) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 15 at 4:37 PM |
| Mavyret Could Amplify Gilead's HCV Pain - Seeking Alpha
seekingalpha.com - August 15 at 2:24 AM |
| AbbVie, Inc. – Value Analysis (NYSE:ABBV) : August 14, 2017
finance.yahoo.com - August 14 at 9:20 PM |
| See what the IHS Markit Score report has to say about AbbVie Inc.
finance.yahoo.com - August 11 at 3:31 PM |
| AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : August 11, 2017
finance.yahoo.com - August 11 at 3:31 PM |
| AbbVie a Top 25 Dividend Giant With 3.56% Yield (ABBV)
www.nasdaq.com - August 10 at 9:50 PM |
| First Business Financial Services, Inc. Buys iShares Russell 1000 Growth, AbbVie Inc, Aetna ... - Nasdaq
www.nasdaq.com - August 10 at 4:50 PM |
| First Business Financial Services, Inc. Buys iShares Russell 1000 Growth, AbbVie Inc, Aetna ... - Nasdaq
www.nasdaq.com - August 10 at 4:50 PM |
| Celgene’s Otezla Witnessed High Revenue Growth in 2Q17
finance.yahoo.com - August 10 at 4:49 PM |
| Celgene’s Otezla Witnessed High Revenue Growth in 2Q17
finance.yahoo.com - August 10 at 4:49 PM |
| Traders Buy High Volume of AbbVie Put Options (NYSE:ABBV)
www.americanbankingnews.com - August 10 at 7:38 AM |
| Gratus Capital LLC Buys AbbVie Inc, Edwards Lifesciences Corp, Sysco Corp, Sells Schwab US ... - Nasdaq
www.nasdaq.com - August 10 at 1:29 AM |
| Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data
finance.yahoo.com - August 9 at 3:21 PM |
| AbbVie Inc. (NYSE:ABBV) Chairman Sells $13,712,301.00 in Stock
www.americanbankingnews.com - August 8 at 10:28 PM |
 | AbbVie Wages HCV Drug-Price War on Gilead - Bloomberg Gadfly - Bloomberg
www.bloomberg.com - August 8 at 3:21 PM |
 | NCCN Foundation Announces Fifth 2017 Young Investigator Award
www.prnewswire.com - August 7 at 4:23 PM |
| Weekly Top Insider Buys Highlight for the Week of August 4
www.nasdaq.com - August 7 at 4:23 PM |
| AbbVie's Mavyret Approved for Commercialization in US
finance.yahoo.com - August 7 at 4:23 PM |
| Imbruvica Could Significantly Drive AbbVie’s Revenue Growth
finance.yahoo.com - August 7 at 4:23 PM |
| Upadacitinib: Opportunity for AbbVie’s Long-Term Growth?
finance.yahoo.com - August 7 at 4:23 PM |
| Top 4 Marijuana Stocks to Watch for August 2017
finance.yahoo.com - August 7 at 4:23 PM |
| An Update on AbbVie’s Clinical Pipeline in 2017
finance.yahoo.com - August 7 at 4:23 PM |
| AbbVie Inc. (ABBV) Downgraded by BidaskClub
www.americanbankingnews.com - August 6 at 1:56 PM |
 | The Ratings Game: AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games
www.marketwatch.com - August 6 at 10:52 AM |
| Analysts Anticipate AbbVie Inc. (ABBV) Will Announce Quarterly Sales of $6.97 Billion
www.americanbankingnews.com - August 5 at 7:06 AM |
| Insider Selling: AbbVie Inc. (ABBV) Chairman Sells 87,899 Shares of Stock
www.americanbankingnews.com - August 4 at 7:36 PM |
| AbbVie Inc. (ABBV) CEO Richard A. Gonzalez Sells 65,861 Shares
www.americanbankingnews.com - August 4 at 7:36 PM |
| AbbVie's new, cheaper hepatitis C drug could launch the drug world's own Hunger Games - MarketWatch
www.marketwatch.com - August 4 at 3:22 PM |
| Analysts Recommendations for AbbVie in August 2017
finance.yahoo.com - August 4 at 3:22 PM |
| How Did AbbVie Perform in 2Q17?
finance.yahoo.com - August 4 at 3:22 PM |
| NBIX: Strong Start to INGREZZA® Launch
finance.yahoo.com - August 4 at 3:22 PM |
AbbVie (ABBV) Chart for Wednesday, August, 23, 2017
